ArticleScientific reports2026
A novel nomogram incorporating lymphovascular invasion to predict lymph node invasion in high-risk prostate cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accurate preoperative prediction of lymph node invasion (LNI) is essential for selecting candidates for extended pelvic lymph node dissection (ePLND) in high-risk prostate cancer. Although ePLND provides the most reliable nodal staging, it is associated with increased operative time and postoperative complications. Existing predictive models have limited validation in Asian populations and rarely incorporate lymphovascular invasion (LVI). We retrospectively analyzed 325 patients with high-risk prostate cancer who underwent radical prostatectomy with ePLND between 2019 and 2023. Multivariable logistic regression was used to identify independent predictors of LNI and to develop a novel nomogram integrating LVI with established clinical parameters. Model performance was evaluated using receiver operating characteristic analysis, calibration curves, clinical impact curves, and decision curve analysis, and compared with the Briganti 2012, Briganti 2017, and MSKCC models. LVI, seminal vesicle invasion, biopsy Gleason grade group, clinical stage, and preoperative prostate-specific antigen were independent predictors of LNI. The proposed model demonstrated discrimination (AUC = 0.89; 95% CI 0.85–0.93) and good calibration. At a 7% risk threshold, 31.3% of ePLND procedures could be avoided while missing only 1.7% of LNI cases. Incorporation of LVI significantly improves preoperative prediction of nodal metastasis and may support more individualized surgical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.